Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2013 - 2020)

Viridian Therapeutics, Inc.\DE's Notes Payables history runs 8 years deep, the most recent figure standing at $4.7 million for Q3 2020.

• On a quarterly basis, Notes Payables rose 18.5% year-over-year to $4.7 million in Q3 2020; TTM through Sep 2020 was $4.7 million, a 18.5% increase from a year earlier, with the FY2019 full-year figure at $4.0 million, up 73.32% from the prior year.
• Notes Payables advanced to $4.7 million in Q3 2020 per VRDN's latest filing, from $3.4 million in the prior quarter.
• Across five years, Notes Payables topped out at $4.7 million in Q3 2020 and bottomed at $289000.0 in Q2 2018.
• The 5-year median for Notes Payables is $2.0 million (2017), against an average of $2.5 million.
• Across the five-year window, Notes Payables slumped 85.4% in 2018 and surged 1273.7% in 2019, its largest moves.
• Year by year, Notes Payables stood at $2.0 million in 2016, then increased by 0.71% to $2.0 million in 2017, then grew by 15.68% to $2.3 million in 2018, then jumped by 73.32% to $4.0 million in 2019, then gained by 18.39% to $4.7 million in 2020.
• Per Business Quant, the three latest VRDN Notes Payables figures stand at $4.7 million (Q3 2020), $3.4 million (Q2 2020), and $4.0 million (Q1 2020).